TY - JOUR
T1 - Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?
AU - Belizna, Cristina
AU - Stojanovich, Ljudmila
AU - Cohen-Tervaert, Jan Willem
AU - Fassot, Céline
AU - Henrion, Daniel
AU - Loufrani, Laurent
AU - Nagy, Gyorgy
AU - Muchardt, Christian
AU - Hasan, Milena
AU - Ungeheuer, Marie Noelle
AU - Arnaud, Laurent
AU - Alijotas-Reig, Jaume
AU - Esteve-Valverde, Enrique
AU - Nicoletti, Ferdinando
AU - Saulnier, Patrick
AU - Godon, Alban
AU - Reynier, Pascal
AU - Chrétien, Jean Marie
AU - Damian, Laura
AU - Omarjee, Loukman
AU - Mahé, Guillaume
AU - Pistorius, Marc Antoine
AU - Meroni, Pier Luigi
AU - Devreese, Katrien
PY - 2018/8/1
Y1 - 2018/8/1
N2 - © 2018 Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing.
AB - © 2018 Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing.
KW - Antiphospholipid syndrome
KW - Primary antiphospholipid syndrome
KW - Secondary antiphospholipid syndrome
U2 - 10.1016/j.autrev.2018.01.027
DO - 10.1016/j.autrev.2018.01.027
M3 - Review article
C2 - 29885541
SN - 1568-9972
VL - 17
SP - 739
EP - 745
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 8
ER -